Loading clinical trials...
Loading clinical trials...
A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)
Conditions
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010)
Insulin glargine (HOE901)
+1 more
Locations
236
United States
Investigational Site Number 840607
Birmingham, Alabama, United States
Investigational Site Number 840570
Sun City, Arizona, United States
Investigational Site Number 840562
Tempe, Arizona, United States
Investigational Site Number 840577
Tucson, Arizona, United States
Investigational Site Number 840517
Little Rock, Arkansas, United States
Investigational Site Number 840537
Little Rock, Arkansas, United States
Start Date
January 1, 2014
Primary Completion Date
July 1, 2015
Completion Date
July 1, 2015
Last Updated
May 9, 2017
NCT07232537
NCT06815081
NCT06003153
NCT06278207
NCT07051005
NCT07296484
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions